April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
VEGF Plasma levels after intravitreal injection of aflibercept and ranibizumab
Author Affiliations & Notes
  • Martina T Kralinger
    Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria
  • Claus Zehetner
    Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria
  • Inga Waltl
    Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria
  • Rudolf Kirchmayr
    Internal Medicine, Medical University, Innsbruck, Austria
  • Gerhard F. Kieselbach
    Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria
  • Footnotes
    Commercial Relationships Martina Kralinger, None; Claus Zehetner, None; Inga Waltl, None; Rudolf Kirchmayr, None; Gerhard Kieselbach, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4965. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Martina T Kralinger, Claus Zehetner, Inga Waltl, Rudolf Kirchmayr, Gerhard F. Kieselbach; VEGF Plasma levels after intravitreal injection of aflibercept and ranibizumab. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4965.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To determine the level of vascular endothelial growth factor (VEGF) in patients with exudative macular degeneration before and after intravitreal injection of aflibercept and ranibizumab.

Methods: A total of 25 patients with exudative AMD were identified for enrollment in this prospective, randomized, controlled study. Fifteen of these patients were treated with intravitreal aflibercept (2mg) while 10 patients received ranibizumab (0,5mg). Blood samples were obtained before intravitreal injection and two and four weeks after injection. The concentration of the plasma samples was measured by ELISA.

Results: The VEGF levels in patients treated with ranibizumab did not change significantly from baseline 91.3±59.9 (range 15-217) pg/ml to 135.5±133.3 (range 10-473) pg/ml at 7 days and 77.1±46.6 (range 43-178) pg/ml at 4 weeks of follow-up. One week after injection of aflibercept a decrease from baseline VEGF plasma levels ranging between 35 and 58pg/ml below 9 pg/ml was observed in all samples. At four weeks an increase to 20 and 51 pg/ml occurred in two patients while in the other 3 patients the VEGF levels remained below 9pg/ml. Final statistical analyses will be done after analyses of the residual 30 samples of the aflibercept group that is in progress currently.

Conclusions: So far our results are in agreement with the data presented by Avery at the ASRS in Toronto this year showing a reduction of plasma levels after aflibercept while no systemic effect of ranibizumab was observed.

Keywords: 412 age-related macular degeneration  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×